公开(公告)号：US20240021277A1

公开(公告)日：2024-01-18

申请号：US17864393

申请日：2022-07-14

申请人： William Scott HOPKINS ,  Centre for Eye and Vision Research Limited ,  The Hong Kong Polytechnic University

发明人： Myo Win ZAW ,  William Scott HOPKINS ,  Ming Yan, Allen CHEONG

IPC分类号： G16C20/50 ,  G16C20/70

CPC分类号： G16C20/50 ,  G16C20/70

摘要： A machine learning system predicts a physicochemical property (e.g., lipophilicity) of candidate small molecules for pharmaceuticals. A machine learning model is constructed that is trained from a database of small molecule physicochemical properties including known lipophilicity and known retention time in a liquid chromatography column to create a learned association between lipophilicity and liquid chromatography retention time. A candidate small molecule having unknown lipophilicity and unknown retention time is applied to a liquid chromatography column. The retention time of the candidate small molecule in the liquid chromatography column is measured. The measured retention time in the liquid chromatography column is applied to the machine learning model to obtain lipophilicity for the candidate small molecule. One or more candidate small molecules having a lipophilicity value from approximately 1 to approximately 3 are selected from the machine learning model. The identified candidate small molecules are tested for pharmaceutical activity.

公开(公告)号：US20240342149A1

公开(公告)日：2024-10-17

申请号：US18332751

申请日：2023-06-12

申请人： Centre for Eye and Vision Research Limited ,  The Hong Kong Polytechnic University

发明人： Chuen LAM ,  Ying Hon SZE ,  Yan Yin TSE

IPC分类号： A61K31/4439 ,  A61P27/10

CPC分类号： A61K31/4439 ,  A61P27/10

摘要： A pharmacologic treatment of refractive disorders, specifically myopia or hyperopia, by targeting the PPAR signaling pathway using a PPARγ agonist without any binding to PPARα. It is demonstrated that the PPARγ agonist modulates ocular growth through therapeutic intervention at the protein level of the PPAR signaling pathway. The effectiveness of the PPARγ agonist in regulating the PPAR signaling pathway and its associated proteins, as evidenced by experiments using a lens-induced myopia (LIM) animal model. More particularly, it is also demonstrated that the pharmacological reduction of myopic eye growth in terms of biometrics with dosage effect through the administration of the PPARγ agonist.

公开(公告)号：US20240037715A1

公开(公告)日：2024-02-01

申请号：US18360850

申请日：2023-07-28

申请人： Benjamin Simon THOMPSON ,  Centre for Eye and Vision Research Limited ,  The Hong Kong Polytechnic University

发明人： Benjamin Simon THOMPSON ,  Chi Ho TO ,  Yan Yin TSE ,  Ka Man CHUN ,  Elie Aymard Jonathan DE LESTRANGE-ANGINIEUR

IPC分类号： G06T5/00 ,  G02B27/00

CPC分类号： G06T5/002 ,  G02B27/0093 ,  G06T2207/30041

摘要： Methods, systems and devices for preventing and/or retarding myopia onset and/or progression are provided. Particularly, the system for preventing and/or retarding myopia onset and/or progression including an eye tracker, a display, a controller, and a dynamic blurring filter for the visual content on the display. The display is first presented to a subject, then the eye tracker is employed to detect the movement and the location of the subject's eyes and generate a tracking signal. The tracking signal is further processed by the controller to determine a gaze point of the subject's eye on the display. Based on the gaze point, a dynamic blurring filter is created and applied onto the display.

公开(公告)号：US20240261220A1

公开(公告)日：2024-08-08

申请号：US18106205

申请日：2023-02-06

申请人： JUEWEN LIU ,  YIBO LIU ,  CENTRE FOR EYE AND VISION RESEARCH LIMITED ,  THE HONG KONG POLYTECHNIC UNIVERSITY

发明人： MAN-SAU WONG ,  KA-YING WONG ,  JUEWEN LIU ,  YIBO LIU

IPC分类号： A61K9/127 ,  A61K38/13 ,  A61K47/54 ,  A61P27/02

CPC分类号： A61K9/127 ,  A61K38/13 ,  A61K47/549 ,  A61P27/02

摘要： Provided herein are aptamer functionalized liposomes for delivery of ocular drug for eye diseases (such as dry eye disease), products comprising the same and method for preventing and/or treating eye diseases using the same. The aptamer functionalized liposomes, product and method of the present application can be used to effectively delivering ocular drug with extended retention time and high protective effect.

公开(公告)号：US20240360458A1

公开(公告)日：2024-10-31

申请号：US18596647

申请日：2024-03-06

申请人： Juewen LIU ,  Ka-Ying WONG ,  Yibo LIU ,  Chau-Minh PHAN ,  Lyndon JONES ,  Centre for Eye and Vision Research Limited

发明人： Juewen LIU ,  Ka-Ying WONG ,  Yibo LIU ,  Chau-Minh PHAN ,  Lyndon JONES

IPC分类号： C12N15/115 ,  A61K9/00 ,  A61K9/127 ,  A61K45/06 ,  A61P27/02

CPC分类号： C12N15/115 ,  A61K9/0051 ,  A61K9/127 ,  A61K45/06 ,  A61P27/02

摘要： The present invention introduces drug-loaded vehicles conjugated with aptamers, comprising DNA, RNA, or modified nucleic acid sequences designed to selectively and strongly bind to specific target sites on the eye, as well as binding to an ocular device such as a contact lens. Additionally, this innovative approach offers a targeted and sustained drug delivery method, addressing issues such as burst release of drugs, poor affinity between drug and material, and non-targeted drug delivery, while maintaining non-invasiveness and convenience.